BioXcel Therapeutics Inc
NASDAQ:BTAI
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5683
  • TODAY'S CHANGE (%)
    0.0479 (9.2045%)
  • Bid / Lots
    0.5400/ 1
  • Ask / Lots
    0.5700/ 2
  • Open / Previous Close
    0.5460 / 0.5204
  • Day Range
    0.5200
    0.5699
  • 52 Week Range
    0.5000
    4.8908
  • Volume
    447,988

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BTAI
BioXcel Therapeutics Inc
21.2M
-0.2x
---
CYTH
Cyclo Therapeutics Inc
17.6M
-0.8x
---
CHHE
China Health Industries Holdings Inc
21.3M
-15.6x
---
ENMI
DH Enchantment Inc
19.5M
-25.5x
---
PYPD
PolyPid Ltd
23.3M
-0.4x
---
BGXX
Bright Green Corp
15.3M
-1.5x
---
As of 2024-11-15

Company Information

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Contact Information

Headquarters
555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107
Phone
203-643-8060
Fax
302-636-5454

Executives

Lead Independent Chairman of the Board
Peter Mueller
President, Chief Executive Officer, Director
Vimal Mehta
Chief Financial Officer, Senior Vice President
Richard Steinhart
Executive Vice President, Chief Scientific Officer
Frank Yocca
Executive Vice President, Chief of Product Development and Medical Officer
Vincent O'Neill

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$21.2M
Revenue (TTM)
$2.4M
Shares Outstanding
40.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.18
EPS
$-3.56
Book Value
$-1.89
P/E Ratio
-0.2x
Price/Sales (TTM)
8.8
Price/Cash Flow (TTM)
---
Operating Margin
-4,562.26%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.